In summary, we provided reliable data to demonstrate that MUS81 targeting amplified the activation of innate immune response and promoted the anticancer effect of WEE1 inhibitor and ICB combination therapy in gastric cancer (Fig. 7). Here, MUS81 is linked to gastric cancer.